Results 261 to 270 of about 89,537 (296)

JAK inhibitors in dermatology

Indian Journal of Skin Allergy, 2023
The four Janus Kinase (JAK) proteins and seven signal transducer and activator of transcription (STAT) factors mediate the intracellular signaling pathway of cytokine receptors, which are described in the pathogenesis of many autoimmune, allergic, and inflammatory dermatoses.
S. K. Shahriar Ahmed, Abhishek De, Aarti Sarda, Kiran Godse, Sandipan Dhar   +4 more
openaire   +1 more source

JAK inhibitors for the treatment of vitiligo

Journal of Dermatological Science
Vitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids and tacrolimus have been used as topical treatments. Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged.
Shintaro, Inoue, Tamio, Suzuki, Shigetoshi, Sano, Ichiro, Katayama   +3 more
openaire   +2 more sources

Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency [PDF]

Frontiers in Immunology
Fadeeva Mariia, Raykina Elena, Karaulov Alexander   +2 more
exaly   +2 more sources

JAK Inhibitors in Solid Organ Transplantation

The Journal of Clinical Pharmacology, 2023
AbstractJanus kinase (JAK) inhibitors are a novel group of immunosuppressive drugs approved to treat certain rheumatic and allergic disorders; however, their efficacy in the regulation of alloimmune responses after solid organ transplantation has not yet been elucidated.
Sara Assadiasl, Hanieh Mojtahedi, Mohammad Hossein Nicknam   +2 more
openaire   +2 more sources

JAK Protein Kinase Inhibitors

Drug News & Perspectives, 2005
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire   +2 more sources

[JAK inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2013
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire   +1 more source

Combination of JAK inhibitor and immune checkpoint inhibitor in clinical trials: a breakthrough [PDF]

Frontiers in Immunology
Zhongnan Ma
exaly   +2 more sources

[JAK Inhibitors in Rheumatology].

Deutsche medizinische Wochenschrift (1946), 2019
In Germany, baricitinib and tofacitinib have been approved for the treatment of at least moderately active rheumatoid arthritis after the failure of conventional disease modifying anti-rheumatic drugs in 2017, and tofacitinib also for psoriatic arthritis and ulcerative colitis. Both baricitinib and tofacitinib can be taken orally and reversibly inhibit
openaire   +2 more sources

Beyond JAK inhibitor therapy in myelofibrosis

Hematology, 2013
AbstractMyelofibrosis (MF), including primary MF, postpolycythemia vera MF, and postessential thrombocythemia MF, is a clonal stem cell disorder characterized by BM fibrosis, extramedullary hematopoiesis, and a variable propensity to transform into acute leukemia. Allogeneic stem cell transplantation is the only known cure for MF, but its applicability
openaire   +2 more sources

Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial

Journal of Allergy and Clinical Immunology, 2021
Irène Braithwaite, Hart S Dengler, Mark Zak   +2 more
exaly